ClinicalTrials.gg
CompletedNCT04852978Updated Oct 20, 2025Results posted

COVID-19 Study to Assess Immunogenicity, Safety, and Tolerability of Moderna mRNA-1273 Vaccine Administered With Casirivimab+Imdevimab in Healthy Adult Volunteers

A Phase 2 interventional study of casirivimab+imdevimab and Moderna mRNA-1273 vaccine in Healthy and Chronic Stable Illness, sponsored by Regeneron Pharmaceuticals. Completed at 6 sites in United States. Open to participants aged 18 Years to 90 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-20.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
295
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

The primary objectives of the study are:

  • To evaluate the extent of effect, if any, of REGN10933+REGN10987 administration on vaccine-induced neutralizing antibody responses to SARS-CoV-2 by Moderna mRNA-1273
  • To evaluate the time interval required between REGN10933+REGN10987 administration and Moderna mRNA-1273 vaccination, to ensure no meaningful impact on vaccine-induced neutralizing antibody responses to SARS-CoV-2

The secondary objectives of the study are:

  • To quantify the alteration of antigen specificity of vaccine-induced SARS-CoV-2 antibody responses when administered with different dose regimens of REGN10933+REGN10987
  • To evaluate the safety and tolerability of REGN10933+REGN10987 and Moderna mRNA-1273 vaccine when administered in close succession
  • To assess the concentrations of REGN10933 and REGN10987 in serum over time in participants who receive REGN10933+REGN10987 and Moderna mRNA-1273 vaccine
  • To evaluate the immunogenicity of REGN10933 and REGN10987 over time
02

Conditions studied

  • Healthy
  • Chronic Stable Illness
03

In context

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  1. Healthy or has chronic medical condition(s) that are stable and well-controlled in the opinion of the investigator and that are not likely to require significant medical intervention through the end of study
  2. Willing and able to comply with study visits and study-related procedures, including compliance with site precautionary requirements related to SARS-CoV-2 infection and transmission

Key Exclusion Criteria:

  1. Positive RT-PCR test result for SARS-CoV-2 infection at screening or baseline
  2. Positive serology test result for anti-SARS-CoV-2 antibodies at screening or baseline
  3. COVID-19 diagnosis, positive SARS-CoV-2 infection, or positive SARS-CoV-2 serology at any time prior to screening
  4. Previously received an , authorized, or approved coronavirus vaccine (eg, SARS-CoV-2 vaccine, MERS-CoV vaccine)
  5. Currently enrolled in, or has plans to enroll in, any interventional study to prevent or treat COVID-19
  6. Received investigational or approved passive antibodies for SARS-CoV-2 infection prophylaxis ad defined in the protocol
  7. Received intravenous immunoglobulin (IVIG) or blood products in the last 3 months
  8. Any physical examination findings and/or history of any illness that, in the opinion of the study investigator, might confound the results of the study or pose an additional risk to the subject by study participation
  9. History of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric or neurological disease, as assessed by the investigator, that may confound the results of the study or pose an additional risk to the subject by study participation
  10. Medically attended acute illness or hospitalization (ie, >24 hours) for any reason within 30 days prior to screening
  11. Clinical history of myocarditis and/or pericarditis

Note: Other protocol-defined Inclusion/ Exclusion Criteria apply

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
295 participants (actual)

Study arms

  • Experimental
    Wave 1 Dose 1

    Drug: casirivimab+imdevimab · Biological: Moderna mRNA-1273 vaccine

  • Experimental
    Wave 1 Dose 2

    Drug: casirivimab+imdevimab · Biological: Moderna mRNA-1273 vaccine

  • Experimental
    Wave 1 Dose 3

    Drug: casirivimab+imdevimab · Biological: Moderna mRNA-1273 vaccine

  • Experimental
    Wave 1 Vaccine only

    Biological: Moderna mRNA-1273 vaccine

  • Experimental
    Wave 2 Dose 1

    Drug: casirivimab+imdevimab · Biological: Moderna mRNA-1273 vaccine

  • Experimental
    Wave 2 Dose 2

    Drug: casirivimab+imdevimab · Biological: Moderna mRNA-1273 vaccine

  • Experimental
    Wave 2 Vaccine only

    Biological: Moderna mRNA-1273 vaccine

  • Experimental
    Wave 3 Dose 1

    Drug: casirivimab+imdevimab · Biological: Moderna mRNA-1273 vaccine

  • Experimental
    Wave 3 Dose 2

    Drug: casirivimab+imdevimab · Biological: Moderna mRNA-1273 vaccine

  • Experimental
    Wave 3 Vaccine only

    Biological: Moderna mRNA-1273 vaccine

  • Experimental
    Wave 4 Dose 1

    Drug: casirivimab+imdevimab · Biological: Moderna mRNA-1273 vaccine

  • Experimental
    Wave 4 Vaccine only

    Biological: Moderna mRNA-1273 vaccine

Interventions

  • Drugcasirivimab+imdevimab

    Wave 1 Intravenous (IV) administration Wave 2 Subcutaneous administration

    Also known as: REGN10933, REGN10987, REGN-COV2, REGEN-COV™, Ronapreve™

  • BiologicalModerna mRNA-1273 vaccine

    Single intramuscular (IM) injection

06

What researchers measure

Primary outcomes

  1. 50% Inhibitory Dilution (ID50) Titers of Vaccine-induced Neutralizing Antibodies to the SARS-CoV-2 S Protein in Individuals Who Received High Dose REGN10933+REGN10987 (1200 mg)

    High dose - (1200 mg arms)

    Time frame: 56 days after first dose of vaccine

  2. 50% Inhibitory Dilution (ID50) Titers of Vaccine-induced Neutralizing Antibodies to the SARS-CoV-2 S Protein in Individual Who Received Submaximal Dose Levels of REGN10933+REGN10987 (Less Than 1200 mg)

    Submaximal dose - (150 mg, 300 mg, 600 mg, 48 mg, and 12 mg)

    Time frame: 56 days after first dose of vaccine

Secondary outcomes

  1. Absolute Values in Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgA)

    Anti-S1-RBD protein

    Time frame: Up to 365 Days from 1st dose of Vaccination

  2. Median Fold Change of Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgA)

    Anti-S1-RBD protein. Fold Change based on medians = (median value in vaccine only arm / median value in the active arm)

    Time frame: Up to 365 Days from 1st dose of Vaccination

  3. Relative Difference Expressed as a Percent in Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgA)

    Anti-S1-RBD protein. Relative difference is calculated as: \[(LS Geometric Mean Active Arm - LS Geometric Mean Vaccine Alone Arm) / LS Geometric Mean Vaccine Alone Arm\] x 100%

    Time frame: Up to 365 Days from 1st dose of Vaccination

  4. Absolute Values in Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgA)

    \- Anti-S protein (Spike protein)

    Time frame: Up to 365 Days from 1st dose of Vaccination

  5. Fold Change of Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgA)

    Anti-S protein Fold Change based on medians = (median value in vaccine only arm / median value in the active arm)

    Time frame: Up to 365 Days from 1st dose of vaccination

  6. Relative Difference Expressed as a Percent in Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgA)

    Anti-S protein Relative difference is calculated as: \[(LS Geometric Mean Active Arm - LS Geometric Mean Vaccine Alone Arm) / LS Geometric Mean Vaccine Alone Arm\] x 100%

    Time frame: Up to 365 Days from 1st dose of Vaccination

  7. Absolute Values in Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgG)

    Anti-S protein

    Time frame: Up to 365 Days from 1st dose of vaccination

  8. Fold Change of Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgG)

    Anti-S protein Fold Change based on medians = (median value in vaccine only arm / median value in the active arm)

    Time frame: Up to 365 Days from 1st dose of vaccination

  9. Relative Difference Expressed as a Percent in Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgG)

    Anti-S protein (Spike) Relative difference is calculated as: \[(LS Geometric Mean Active Arm - LS Geometric Mean Vaccine Alone Arm) / LS Geometric Mean Vaccine Alone Arm\] x 100%

    Time frame: Up to 365 Days from 1st dose of vaccination

  10. Absolute Values in Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgG)

    Anti-S1-RBD

    Time frame: Up to 365 Days from 1st dose of vaccination

  11. Fold Change of Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgG)

    Anti-S1-RBD protein Fold Change based on medians = (median value in vaccine only arm / median value in the active arm)

    Time frame: Up to 365 Days from 1st dose of vaccination

  12. Relative Difference Expressed as a Percent in Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgG)

    Anti-S1-RBD protein Relative difference is calculated as: \[(LS Geometric Mean Active Arm - LS Geometric Mean Vaccine Alone Arm) / LS Geometric Mean Vaccine Alone Arm\] x 100%

    Time frame: Up to 365 Days from 1st dose of vaccination

  13. Absolute Values in Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgM)

    Anti-S1-RBD

    Time frame: Up to 365 Days from 1st dose of vaccination

  14. Relative Difference Expressed as a Percent in Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgM)

    Anti-S1-RBD protein Relative difference is calculated as: \[(LS Geometric Mean Active Arm - LS Geometric Mean Vaccine Alone Arm) / LS Geometric Mean Vaccine Alone Arm\] x 100%

    Time frame: Up to 365 Days from 1st dose of vaccination

  15. Fold Change of Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgM)

    Anti-S1-RBD protein Fold Change based on medians = (median value in vaccine only arm / median value in the active arm)

    Time frame: Up to 365 Days from 1st dose of vaccination

  16. Absolute Values in Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgM)

    Anti-S protein (Spike protein)

    Time frame: Up to 365 Days from 1st dose of vaccination

  17. Relative Difference Expressed as a Percent in Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgM)

    Anti-S protein (Spike protein) Relative difference is calculated as: \[(LS Geometric Mean Active Arm - LS Geometric Mean Vaccine Alone Arm) / LS Geometric Mean Vaccine Alone Arm\] x 100%

    Time frame: Up to 365 Days from 1st dose of vaccination

  18. Fold Change of Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgM)

    Anti-S protein (Spike protein) Fold Change based on medians = (median value in vaccine only arm / median value in the active arm)

    Time frame: Up to 365 Days from 1st dose of vaccination

  19. 50% Inhibitory Dilution (ID50) Titers of Vaccine-induced Neutralizing Antibodies to SARS-CoV-2 S Protein Assessed Over Time After the First Dose of Moderna mRNA-1273 Vaccine

    Time frame: Up to 365 Days from 1st dose of vaccination

  20. Number of Participants With Treatment-emergent Adverse Events (TEAEs) Throughout the Study

    Time frame: Up to 401 Days

  21. Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) Throughout the Study

    Time frame: Up to 401 Days

  22. Number of Participants With Infusion-related Reactions (Grade ≥2) to REGN10933+REGN10987

    Time frame: Through Day 4 post-infusion

  23. Number of Participants With Injection Site Reactions (Grade ≥3) to REGN10933+REGN10987

    Time frame: Through Day 4 post-infusion

  24. Number of Participants With Injection Site Reactions (Grade ≥3) to Moderna mRNA-1273 Vaccine

    Time frame: Through Day 4 post-infusion

  25. Number of Participants With Hypersensitivity Reactions (Grade ≥2) to REGN10933+REGN10987 or Each Dose of Moderna mRNA-1273 Vaccine

    Grade 2 - characterized by an adverse local or general response from exposure and oral intervention indicated Grade 3 - hospitalization indicated and intravenous response required Grade 4 - Life Threatening consequence and urgent intervention indicated Grade 5 - Death

    Time frame: Through Day 29 post-infusion or post-injection

  26. Concentrations of REGN10933 in Serum Over Time

    Time frame: Up to 182 Days

  27. Concentrations of REGN10987 in Serum Over Time

    Time frame: Up to 182 Days

  28. Immunogenicity, as Measured by Anti-drug Antibodies (ADA) to REGN10987

    Time frame: Up to Day 183

  29. Immunogenicity, as Measured by Anti-drug Antibodies (ADA) to REGN10933

    Time frame: Up to Day 183

  30. Immunogenicity, as Measured by Neutralizing Antibodies (NAb) to REGN10987

    Time frame: Up to Day 183

  31. Immunogenicity, as Measured by Neutralizing Antibodies (NAb) to REGN10933

    Time frame: Up to Day 183

07

Results

Posted Aug 20, 2024

Participant flow

Participant flow — Overall Study
MilestoneVaccine OnlyREGN10933+REGN10987 + Vaccine 1200 mg Day 1 IVREGN10933+REGN10987 + Vaccine 300 mg Day 1 IVREGN10933+REGN10987 + Vaccine 150 mg Day 1 IVREGN10933+REGN10987 + Vaccine 48 mg Day 1 IVREGN10933+REGN10987 + Vaccine 12 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 7 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 1 SCREGN10933+REGN10987 + Vaccine 600 mg Day 1 SC
Started482829283331263535
Completed412324272624222932
Not completed755177463
Withdrew: Physician decision010000020
Withdrew: Sponsor request001000000
Withdrew: Death000000100
Withdrew: Lost to follow-up322024122
Withdrew: Withdrawal by subject422153221

Outcome measures

Primary50% Inhibitory Dilution (ID50) Titers of Vaccine-induced Neutralizing Antibodies to the SARS-CoV-2 S Protein in Individuals Who Received High Dose REGN10933+REGN10987 (1200 mg)

High dose - (1200 mg arms)

Time frame:
56 days after first dose of vaccine
Reported as:
Mean · Titer
50% Inhibitory Dilution (ID50) Titers of Vaccine-induced Neutralizing Antibodies to the SARS-CoV-2 S Protein in Individuals Who Received High Dose REGN10933+REGN10987 (1200 mg)
TiterVaccine OnlyREGN10933+REGN10987 + Vaccine 1200 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 1 SCREGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV
50% Inhibitory Dilution (ID50) Titers of Vaccine-induced Neutralizing Antibodies to the SARS-CoV-2 S Protein in Individuals Who Received High Dose REGN10933+REGN10987 (1200 mg)2594.9 ± 1981.51818.6 ± 2365.8980.8 ± 1015.12576.8 ± 2736.1
Primary50% Inhibitory Dilution (ID50) Titers of Vaccine-induced Neutralizing Antibodies to the SARS-CoV-2 S Protein in Individual Who Received Submaximal Dose Levels of REGN10933+REGN10987 (Less Than 1200 mg)

Submaximal dose - (150 mg, 300 mg, 600 mg, 48 mg, and 12 mg)

Time frame:
56 days after first dose of vaccine
Reported as:
Mean · Titer
50% Inhibitory Dilution (ID50) Titers of Vaccine-induced Neutralizing Antibodies to the SARS-CoV-2 S Protein in Individual Who Received Submaximal Dose Levels of REGN10933+REGN10987 (Less Than 1200 mg)
TiterVaccine OnlyREGN10933+REGN10987 + Vaccine 300 mg Day 1 IVREGN10933+REGN10987 + Vaccine 150 mg Day 1 IVREGN10933+REGN10987 + Vaccine 48 mg Day 1 IVREGN10933+REGN10987 + Vaccine 12 mg Day 1 IVREGN10933+REGN10987 + Vaccine 600 mg Day 1 SC
50% Inhibitory Dilution (ID50) Titers of Vaccine-induced Neutralizing Antibodies to the SARS-CoV-2 S Protein in Individual Who Received Submaximal Dose Levels of REGN10933+REGN10987 (Less Than 1200 mg)2594.9 ± 1981.5780.8 ± 771.1716.1 ± 664.94922.8 ± 11157.32422.2 ± 2882.71549.5 ± 4334.1
SecondaryAbsolute Values in Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgA)

Anti-S1-RBD protein

Time frame:
Up to 365 Days from 1st dose of Vaccination
Reported as:
Mean · Binding Antibody Unit (BAU)/mL
Absolute Values in Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgA)
Binding Antibody Unit (BAU)/mLVaccine OnlyREGN10933+REGN10987 + Vaccine 1200 mg Day 1 IVREGN10933+REGN10987 + Vaccine 300 mg Day 1 IVREGN10933+REGN10987 + Vaccine 150 mg Day 1 IVREGN10933+REGN10987 + Vaccine 48 mg Day 1 IVREGN10933+REGN10987 + Vaccine 12 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 7 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 1 SCREGN10933+REGN10987 + Vaccine 600 mg Day 1 SC
Baseline18.7 ± 9.215.7 ± 0.020.7 ± 25.215.7 ± 0.020.1 ± 11.624.4 ± 22.522.6 ± 14.420.2 ± 11.217.6 ± 10.5
6 Days after 1st Vaccine47.5 ± 31.8—————352.9 ± 1590.7——
14 Days after 1st Vaccine1176.5 ± 1758.5884.0 ± 860.01510.6 ± 2141.5730.4 ± 963.2638.6 ± 662.1673.7 ± 871.01046.0 ± 1726.31184.6 ± 1716.7902.0 ± 1485.9
28 Days after 1st Vaccine373.0 ± 416.1276.3 ± 461.4297.8 ± 514.2171.9 ± 193.1209.0 ± 207.0246.0 ± 451.3592.3 ± 1587.1351.0 ± 566.1259.4 ± 520.4
42 Days after 1st Vaccine2610.7 ± 2032.32318.5 ± 2387.22190.4 ± 2163.52022.8 ± 2170.31989.5 ± 1797.01246.5 ± 1017.91460.5 ± 1724.81714.4 ± 1779.31763.1 ± 1444.0
56 Days after 1st Vaccine1327.7 ± 1497.71146.2 ± 1738.7769.1 ± 836.1845.9 ± 1056.3787.9 ± 630.1669.4 ± 813.7841.7 ± 1587.0889.6 ± 1475.2732.0 ± 785.6
168 Days after 1st Vaccine1825.0 ± 2690.3986.3 ± 1718.1358.8 ± 610.31211.0 ± 2194.51772.6 ± 2353.2871.1 ± 1584.93053.1 ± 3077.9715.2 ± 1658.4346.2 ± 888.1
252 Days after 1st Vaccine3665.4 ± 3141.03488.8 ± 3126.53180.0 ± 3171.63174.7 ± 2840.81508.8 ± 1831.01539.2 ± 1681.92898.1 ± 2674.84269.9 ± 3316.23556.1 ± 3122.6
365 Days after 1st Vaccine2722.7 ± 2680.03904.4 ± 3036.12804.1 ± 2533.83008.7 ± 2609.02180.7 ± 1934.92155.8 ± 2369.22727.5 ± 2632.93193.5 ± 2890.23136.9 ± 2864.3
SecondaryMedian Fold Change of Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgA)

Anti-S1-RBD protein. Fold Change based on medians = (median value in vaccine only arm / median value in the active arm)

Time frame:
Up to 365 Days from 1st dose of Vaccination
Reported as:
Number · Fold Change
Median Fold Change of Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgA)
Fold ChangeREGN10933+REGN10987 + Vaccine 1200 mg Day 1 IVREGN10933+REGN10987 + Vaccine 300 mg Day 1 IVREGN10933+REGN10987 + Vaccine 150 mg Day 1 IVREGN10933+REGN10987 + Vaccine 48 mg Day 1 IVREGN10933+REGN10987 + Vaccine 12 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 7 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 1 SCREGN10933+REGN10987 + Vaccine 600 mg Day 1 SC
6 Days after 1st Vaccine—————3.2——
14 Days after 1st Vaccine0.80.61.61.11.91.31.01.3
28 Days after 1st Vaccine1.72.02.61.92.71.71.42.4
42 Days after 1st Vaccine1.51.61.71.91.92.32.11.4
56 Days after 1st Vaccine1.52.01.81.72.43.02.02.3
168 Days after 1st Vaccine1.84.31.81.01.10.22.93.6
252 Days after 1st Vaccine1.01.41.34.23.21.30.71.0
365 Days after 1st Vaccine0.40.90.90.91.21.00.70.9
SecondaryRelative Difference Expressed as a Percent in Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgA)

Anti-S1-RBD protein. Relative difference is calculated as: \[(LS Geometric Mean Active Arm - LS Geometric Mean Vaccine Alone Arm) / LS Geometric Mean Vaccine Alone Arm\] x 100%

Time frame:
Up to 365 Days from 1st dose of Vaccination
Reported as:
Geometric least squares mean · Percent
Relative Difference Expressed as a Percent in Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgA)
PercentREGN10933+REGN10987 + Vaccine 1200 mg Day 1 IVREGN10933+REGN10987 + Vaccine 300 mg Day 1 IVREGN10933+REGN10987 + Vaccine 150 mg Day 1 IVREGN10933+REGN10987 + Vaccine 48 mg Day 1 IVREGN10933+REGN10987 + Vaccine 12 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 7 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 1 SCREGN10933+REGN10987 + Vaccine 600 mg Day 1 SC
Baseline-9.8 (-24.4 to 7.5)-2.3 (-18.1 to 16.6)-10.1 (-24.7 to 7.2)5.0 (-11.6 to 24.8)13.7 (-5.1 to 36.2)13.3 (-5.7 to 36.1)6.0 (-10.2 to 25.2)-4.7 (-19.3 to 12.6)
6 Days after 1st Vaccine—————-28.7 (-80.7 to 163.6)——
14 Days after 1st Vaccine-15.3 (-54.4 to 57.1)-6.2 (-49.9 to 75.5)-43.6 (-69.9 to 5.5)-31.6 (-62.6 to 25.2)-33.9 (-64.9 to 24.7)-35.0 (-65.5 to 22.7)5.2 (-41.5 to 89.2)-3.2 (-46.1 to 73.7)
28 Days after 1st Vaccine-37.3 (-65.1 to 12.6)-48.6 (-71.4 to -7.7)-52.3 (-73.5 to -14.3)-43.6 (-68.2 to -0.1)-51.6 (-73.5 to -11.8)-32.5 (-63.0 to 23.2)-24.0 (-56.2 to 31.8)-50.9 (-71.8 to -14.5)
42 Days after 1st Vaccine-28.3 (-55.9 to 16.6)-28.3 (-55.7 to 16.0)-29.8 (-56.6 to 13.4)-22.3 (-51.4 to 24.3)-53.3 (-72.1 to -21.9)-54.6 (-73.1 to -23.5)-39.4 (-61.4 to -4.7)-32.6 (-57.4 to 6.7)
56 Days after 1st Vaccine-31.6 (-59.9 to 16.9)-44.7 (-67.2 to -6.7)-41.8 (-65.5 to -1.9)-28.9 (-57.4 to 18.5)-59.9 (-76.9 to -30.5)-55.1 (-74.1 to -22.2)-41.9 (-64.5 to -5.1)-40.9 (-64.1 to -2.6)
168 Days after 1st Vaccine-49.8 (-76.6 to 7.6)-71.8 (-86.7 to -4.0)-47.8 (-75.2 to 9.9)7.1 (-49.6 to 127.2)-41.2 (-73.1 to 28.9)66.1 (-25.0 to 267.7)-59.3 (-79.9 to -17.5)-72.7 (-86.6 to -44.5)
252 Days after 1st Vaccine-23.2 (-68.9 to 89.3)-49.4 (-79.5 to 25.2)-16.9 (-65.6 to 100.5)-59.9 (-84.2 to 1.7)-58.1 (-84.4 to 12.6)-23.4 (-70.5 to 99.2)6.9 (-55.3 to 155.8)-26.2 (-68.6 to 73.0)
365 Days after 1st Vaccine78.4 (-10.0 to 253.7)0.6 (-48.8 to 97.9)39.0 (-27.4 to 166.2)3.0 (-47.6 to 102.5)-19.7 (-61.3 to 66.6)19.5 (-40.9 to 141.7)30.4 (-31.5 to 148.3)31.6 (-29.8 to 146.9)
SecondaryAbsolute Values in Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgA)

\- Anti-S protein (Spike protein)

Time frame:
Up to 365 Days from 1st dose of Vaccination
Reported as:
Mean · Binding Antibody Unit (BAU)/mL
Absolute Values in Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgA)
Binding Antibody Unit (BAU)/mLVaccine OnlyREGN10933+REGN10987 + Vaccine 1200 mg Day 1 IVREGN10933+REGN10987 + Vaccine 300 mg Day 1 IVREGN10933+REGN10987 + Vaccine 150 mg Day 1 IVREGN10933+REGN10987 + Vaccine 48 mg Day 1 IVREGN10933+REGN10987 + Vaccine 12 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 7 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 1 SCREGN10933+REGN10987 + Vaccine 600 mg Day 1 SC
Baseline11.7 ± 10.812.8 ± 15.78.5 ± 7.311.6 ± 14.714.2 ± 21.714.7 ± 26.117.3 ± 39.77.7 ± 3.812.9 ± 18.6
6 Days after 1st Vaccine27.1 ± 29.2—————662.5 ± 3155.1——
14 Days after 1st Vaccine1597.4 ± 2367.21319.8 ± 1020.41984.7 ± 2708.31003.7 ± 1102.01020.7 ± 879.1970.4 ± 1165.01636.9 ± 3070.81742.4 ± 2871.01494.4 ± 2303.0
28 Days after 1st Vaccine522.1 ± 466.7400.1 ± 534.2337.5 ± 386.9246.6 ± 207.4321.4 ± 309.2343.1 ± 490.0581.7 ± 1292.8434.5 ± 425.0349.0 ± 518.6
42 Days after 1st Vaccine3147.1 ± 2905.22868.6 ± 2645.02472.4 ± 2243.82765.6 ± 3830.72396.0 ± 1923.41892.7 ± 1462.32089.8 ± 2548.42080.7 ± 1477.72029.1 ± 1652.4
56 Days after 1st Vaccine1393.0 ± 1232.51218.0 ± 1192.6941.5 ± 817.6858.8 ± 849.31013.9 ± 818.1813.1 ± 753.4872.3 ± 1076.61009.6 ± 1182.4911.9 ± 889.7
168 Days after 1st Vaccine2060.3 ± 3446.9931.9 ± 1466.0405.6 ± 568.31378.0 ± 3168.91966.2 ± 3280.91251.0 ± 3206.32982.3 ± 3720.5702.1 ± 1502.8354.8 ± 591.3
252 Days after 1st Vaccine4666.6 ± 5091.43753.9 ± 3919.03940.5 ± 5162.13497.8 ± 3891.31341.3 ± 1963.81911.1 ± 3022.52867.2 ± 3284.65957.8 ± 5727.35012.0 ± 5693.1
365 Days after 1st Vaccine2808.8 ± 2971.83549.5 ± 2982.62703.2 ± 2444.52903.6 ± 3225.52302.4 ± 3101.03204.6 ± 4670.92944.1 ± 3850.83717.2 ± 4290.73648.0 ± 4074.5
SecondaryFold Change of Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgA)

Anti-S protein Fold Change based on medians = (median value in vaccine only arm / median value in the active arm)

Time frame:
Up to 365 Days from 1st dose of vaccination
Reported as:
Number · Fold Change
Fold Change of Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgA)
Fold ChangeREGN10933+REGN10987 + Vaccine 1200 mg Day 1 IVREGN10933+REGN10987 + Vaccine 300 mg Day 1 IVREGN10933+REGN10987 + Vaccine 150 mg Day 1 IVREGN10933+REGN10987 + Vaccine 48 mg Day 1 IVREGN10933+REGN10987 + Vaccine 12 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 7 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 1 SCREGN10933+REGN10987 + Vaccine 600 mg Day 1 SC
Baseline1.01.01.01.01.01.01.01.0
6 Days after 1st Vaccine—————0.7——
14 Days after 1st Vaccine0.80.71.51.01.80.80.81.3
28 Days after 1st Vaccine1.91.92.62.02.72.11.42.8
42 Days after 1st Vaccine1.41.61.71.61.51.51.71.9
56 Days after 1st Vaccine1.51.91.91.52.02.21.72.1
168 Days after 1st Vaccine1.52.21.60.91.10.21.62.6
252 Days after 1st Vaccine0.91.11.33.13.81.20.60.9
365 Days after 1st Vaccine0.61.01.01.01.11.30.81.0
SecondaryRelative Difference Expressed as a Percent in Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgA)

Anti-S protein Relative difference is calculated as: \[(LS Geometric Mean Active Arm - LS Geometric Mean Vaccine Alone Arm) / LS Geometric Mean Vaccine Alone Arm\] x 100%

Time frame:
Up to 365 Days from 1st dose of Vaccination
Reported as:
Geometric least squares mean · Percent
Relative Difference Expressed as a Percent in Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgA)
PercentREGN10933+REGN10987 + Vaccine 1200 mg Day 1 IVREGN10933+REGN10987 + Vaccine 300 mg Day 1 IVREGN10933+REGN10987 + Vaccine 150 mg Day 1 IVREGN10933+REGN10987 + Vaccine 48 mg Day 1 IVREGN10933+REGN10987 + Vaccine 12 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 7 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 1 SCREGN10933+REGN10987 + Vaccine 600 mg Day 1 SC
Baseline0.8 (-26.7 to 38.5)-20.2 (-42.0 to 9.8)-8.8 (-33.6 to 25.4)3.0 (-24.6 to 40.6)-3.2 (-30.2 to 34.1)2.2 (-26.6 to 42.3)-23.1 (-43.0 to 3.7)-5.6 (-30.1 to 27.6)
6 Days after 1st Vaccine—————-2.3 (-80.9 to 398.9)——
14 Days after 1st Vaccine-3.7 (-43.7 to 64.7)1.8 (-40.9 to 75.5)-34.7 (-62.1 to 12.5)-22.9 (-54.4 to 30.4)-27.4 (-58.2 to 25.9)-21.6 (-54.8 to 36.1)10.4 (-33.7 to 83.8)8.8 (-34.6 to 80.7)
28 Days after 1st Vaccine-36.8 (-62.2 to 5.9)-50.5 (-70.5 to -17.1)-53.6 (-72.3 to -22.2)-44.2 (-66.3 to -7.6)-51.8 (-71.6 to -18.2)-40.4 (-64.9 to 1.2)-23.9 (-53.1 to 23.7)-48.7 (-68.5 to -16.4)
42 Days after 1st Vaccine-18.5 (-47.2 to 25.9)-24.0 (-50.6 to 16.7)-25.3 (-51.3 to 14.8)-16.5 (-45.1 to 26.9)-39.4 (-61.7 to -4.1)-39.8 (-62.3 to -4.1)-29.9 (-53.2 to 5.0)-36.7 (-58.0 to -4.5)
56 Days after 1st Vaccine-21.5 (-50.8 to 25.5)-35.0 (-58.9 to 2.7)-42.7 (-63.7 to -9.4)-22.8 (-50.6 to 20.8)-54.5 (-71.9 to -26.3)-47.5 (-67.6 to -15.0)-33.5 (-56.7 to 2.3)-39.9 (-61.1 to -6.9)
168 Days after 1st Vaccine-41.5 (-70.7 to 16.9)-66.8 (-83.3 to -34.2)-46.7 (-72.9 to 4.7)11.4 (-43.8 to 120.6)-36.9 (-69.1 to 28.6)63.2 (-20.7 to 235.9)-56.8 (-77.2 to -17.8)-70.1 (-84.3 to -42.9)
252 Days after 1st Vaccine-23.9 (-68.2 to 82.1)-47.5 (-78.1 to 25.8)-23.6 (-67.4 to 79.1)-63.8 (-85.3 to -11.0)-58.4 (-84.0 to 8.4)-29.9 (-72.1 to 76.5)18.1 (-49.2 to 174.4)-23.9 (-66.6 to 73.5)
365 Days after 1st Vaccine44.4 (-23.5 to 172.5)4.4 (-44.3 to 95.5)11.3 (-39.1 to 103.4)-7.6 (-50.6 to 72.9)-17.6 (-58.2 to 62.3)-0.0 (-48.0 to 92.2)13.2 (-37.7 to 105.8)26.0 (-29.7 to 126.0)
SecondaryAbsolute Values in Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgG)

Anti-S protein

Time frame:
Up to 365 Days from 1st dose of vaccination
Reported as:
Mean · Binding Antibody Unit (BAU)/mL
Absolute Values in Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgG)
Binding Antibody Unit (BAU)/mLVaccine OnlyREGN10933+REGN10987 + Vaccine 1200 mg Day 1 IVREGN10933+REGN10987 + Vaccine 300 mg Day 1 IVREGN10933+REGN10987 + Vaccine 150 mg Day 1 IVREGN10933+REGN10987 + Vaccine 48 mg Day 1 IVREGN10933+REGN10987 + Vaccine 12 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 7 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 1 SCREGN10933+REGN10987 + Vaccine 600 mg Day 1 SC
Baseline4.5 ± 3.98.1 ± 10.44.4 ± 2.73.2 ± 1.25.9 ± 6.759.8 ± 267.15.1 ± 5.43.0 ± 1.44.0 ± 3.3
6 Days after 1st Vaccine4.0 ± 1.8—————624.8 ± 3025.9——
14 Days after 1st Vaccine409.7 ± 527.4600.2 ± 1399.6205.9 ± 175.8256.3 ± 298.91742.9 ± 5319.5497.1 ± 1620.01059.4 ± 3414.4211.8 ± 226.6345.1 ± 679.0
28 Days after 1st Vaccine676.8 ± 878.5468.6 ± 860.3173.3 ± 137.1183.7 ± 168.51450.6 ± 4361.4366.7 ± 1040.5973.5 ± 3309.8318.2 ± 390.6598.7 ± 2096.6
42 Days after 1st Vaccine4900.0 ± 3970.83814.3 ± 3083.22769.7 ± 2535.42816.7 ± 2858.95074.9 ± 6044.32179.8 ± 928.53968.7 ± 3806.82797.7 ± 1787.22852.9 ± 2450.6
56 Days after 1st Vaccine3459.1 ± 3498.43737.3 ± 4638.61841.8 ± 1012.71849.9 ± 1693.23432.9 ± 5246.82227.5 ± 2300.03358.0 ± 4515.31980.6 ± 1470.22361.7 ± 2513.4
168 Days after 1st Vaccine2208.7 ± 3093.82156.7 ± 4354.7900.0 ± 2018.71862.8 ± 3723.42973.3 ± 4045.51346.4 ± 1762.04609.3 ± 5678.3940.1 ± 1486.8729.5 ± 889.1
252 Days after 1st Vaccine6319.0 ± 6625.55682.5 ± 6074.34138.0 ± 5343.07004.3 ± 7077.54784.2 ± 4832.54974.1 ± 6150.06830.1 ± 5394.96806.3 ± 7138.76855.6 ± 7833.3
365 Days after 1st Vaccine5724.1 ± 4944.58865.1 ± 7110.67888.9 ± 7014.87596.9 ± 7438.64954.4 ± 5226.55263.3 ± 6235.83819.3 ± 3262.79836.6 ± 7299.810863.1 ± 7822.4
SecondaryFold Change of Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgG)

Anti-S protein Fold Change based on medians = (median value in vaccine only arm / median value in the active arm)

Time frame:
Up to 365 Days from 1st dose of vaccination
Reported as:
Number · Fold Change
Fold Change of Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgG)
Fold ChangeREGN10933+REGN10987 + Vaccine 1200 mg Day 1 IVREGN10933+REGN10987 + Vaccine 300 mg Day 1 IVREGN10933+REGN10987 + Vaccine 150 mg Day 1 IVREGN10933+REGN10987 + Vaccine 48 mg Day 1 IVREGN10933+REGN10987 + Vaccine 12 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 7 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 1 SCREGN10933+REGN10987 + Vaccine 600 mg Day 1 SC
Baseline0.41.01.01.01.01.01.01.0
6 Days after 1st Vaccine—————0.5——
14 Days after 1st Vaccine1.61.71.83.52.51.02.42.1
28 Days after 1st Vaccine3.14.13.72.83.72.62.32.9
42 Days after 1st Vaccine1.11.51.61.11.41.21.31.4
56 Days after 1st Vaccine1.21.51.81.11.41.61.61.6
168 Days after 1st Vaccine1.71.71.80.41.10.41.31.5
252 Days after 1st Vaccine1.11.40.61.21.20.51.01.2
365 Days after 1st Vaccine0.70.70.91.61.81.40.50.5
SecondaryRelative Difference Expressed as a Percent in Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgG)

Anti-S protein (Spike) Relative difference is calculated as: \[(LS Geometric Mean Active Arm - LS Geometric Mean Vaccine Alone Arm) / LS Geometric Mean Vaccine Alone Arm\] x 100%

Time frame:
Up to 365 Days from 1st dose of vaccination
Reported as:
Geometric least squares mean · Percent
Relative Difference Expressed as a Percent in Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgG)
PercentREGN10933+REGN10987 + Vaccine 1200 mg Day 1 IVREGN10933+REGN10987 + Vaccine 300 mg Day 1 IVREGN10933+REGN10987 + Vaccine 150 mg Day 1 IVREGN10933+REGN10987 + Vaccine 48 mg Day 1 IVREGN10933+REGN10987 + Vaccine 12 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 7 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 1 SCREGN10933+REGN10987 + Vaccine 600 mg Day 1 SC
Baseline58.9 (15.4 to 118.9)3.0 (-25.3 to 41.9)-18.7 (-41.0 to 12.0)18.3 (-13.5 to 61.9)29.4 (-6.9 to 79.8)5.4 (-24.5 to 47.1)-22.9 (-43.0 to 4.2)-10.3 (-33.8 to 21.5)
6 Days after 1st Vaccine—————88.0 (-65.3 to 919.3)——
14 Days after 1st Vaccine-25.1 (-60.2 to 41.0)-48.5 (-72.9 to -2.1)-44.5 (-70.8 to 5.4)-29.9 (-62.2 to 30.2)-47.8 (-72.8 to -0.2)8.2 (-43.5 to 107.0)-34.0 (-63.8 to 20.3)-28.3 (-60.6 to 30.4)
28 Days after 1st Vaccine-45.5 (-70.6 to 1.0)-64.1 (-80.6 to -33.4)-63.4 (-80.3 to -32.1)-33.8 (-63.8 to 21.0)-57.0 (-77.2 to -19.1)-28.4 (-62.0 to 34.9)-38.6 (-65.6 to 9.8)-45.7 (-69.7 to -2.6)
42 Days after 1st Vaccine-25.5 (-52.2 to 16.3)-50.1 (-67.9 to -22.6)-45.9 (-65.1 to -16.0)-15.3 (-44.9 to 30.2)-46.7 (-66.7 to -14.7)-46.4 (-66.8 to -13.5)-35.4 (-57.3 to -2.3)-34.7 (-57.1 to -0.6)
56 Days after 1st Vaccine6.2 (-33.3 to 69.1)-34.8 (-58.6 to 2.8)-36.6 (-59.7 to -0.1)-6.9 (-40.3 to 45.1)-23.6 (-52.7 to 23.3)-18.9 (-49.8 to 30.9)-29.1 (-53.8 to 8.7)-20.9 (-48.8 to 22.1)
168 Days after 1st Vaccine-29.1 (-61.4 to 30.1)-54.2 (-74.9 to -16.5)-29.5 (-61.0 to 27.5)48.6 (-18.4 to 170.8)-9.3 (-51.5 to 69.4)98.9 (5.6 to 274.8)-40.6 (-66.2 to 4.3)-48.0 (-70.5 to -8.3)
252 Days after 1st Vaccine-13.4 (-61.3 to 93.9)-47.4 (-76.6 to 17.9)4.4 (-52.4 to 129.3)-2.6 (-57.6 to 123.5)-5.2 (-60.8 to 129.3)49.1 (-36.4 to 249.7)28.2 (-41.2 to 179.4)-12.2 (-59.0 to 87.9)
365 Days after 1st Vaccine65.6 (-10.0 to 204.6)44.0 (-21.1 to 163.0)38.1 (-22.6 to 146.4)-3.1 (-46.9 to 76.9)-20.2 (-58.3 to 53.0)-23.9 (-59.4 to 42.4)78.7 (0.7 to 217.0)116.6 (23.7 to 279.3)
SecondaryAbsolute Values in Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgG)

Anti-S1-RBD

Time frame:
Up to 365 Days from 1st dose of vaccination
Reported as:
Mean · Binding Antibody Unit (BAU)/mL
Absolute Values in Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgG)
Binding Antibody Unit (BAU)/mLVaccine OnlyREGN10933+REGN10987 + Vaccine 1200 mg Day 1 IVREGN10933+REGN10987 + Vaccine 300 mg Day 1 IVREGN10933+REGN10987 + Vaccine 150 mg Day 1 IVREGN10933+REGN10987 + Vaccine 48 mg Day 1 IVREGN10933+REGN10987 + Vaccine 12 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 7 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 1 SCREGN10933+REGN10987 + Vaccine 600 mg Day 1 SC
Baseline6.6 ± 4.014.0 ± 21.46.8 ± 2.85.6 ± 3.09.0 ± 6.0111.4 ± 512.79.2 ± 8.75.4 ± 2.47.5 ± 10.3
6 Days after 1st Vaccine7.2 ± 2.8—————940.8 ± 4569.2——
14 Days after 1st Vaccine403.4 ± 650.2521.4 ± 1411.9185.9 ± 262.0153.1 ± 218.22830.5 ± 9711.1493.7 ± 1936.31340.3 ± 5510.0159.7 ± 165.2290.9 ± 729.9
28 Days after 1st Vaccine809.4 ± 1100.8448.4 ± 841.7206.0 ± 177.2182.3 ± 214.12050.2 ± 6594.9418.5 ± 1282.01417.6 ± 5411.7353.5 ± 434.6597.0 ± 2153.3
42 Days after 1st Vaccine7638.6 ± 7214.27336.3 ± 6920.74969.6 ± 4706.14776.7 ± 5241.910764.3 ± 17718.43229.9 ± 1467.45665.7 ± 5297.24342.8 ± 3047.24537.6 ± 4153.6
56 Days after 1st Vaccine5595.6 ± 6439.66945.4 ± 10762.43123.9 ± 1915.73148.8 ± 3404.77023.8 ± 14395.74077.9 ± 4581.24864.7 ± 6282.43080.5 ± 2507.43775.4 ± 3840.3
168 Days after 1st Vaccine4007.7 ± 6218.64208.6 ± 9593.81578.5 ± 3810.33438.9 ± 7459.75873.1 ± 9336.12243.6 ± 3035.310359.9 ± 14463.61372.4 ± 2310.71262.8 ± 1957.9
252 Days after 1st Vaccine13505.1 ± 15811.013428.1 ± 15027.89549.2 ± 14673.81487.0 ± 18618.29124.4 ± 11583.711189.1 ± 16641.612902.6 ± 10578.814503.6 ± 19241.817456.8 ± 23681.5
365 Days after 1st Vaccine11268.3 ± 11087.521517.0 ± 23659.316569.7 ± 15884.016959.2 ± 20989.310225.9 ± 13257.711261.7 ± 15375.76301.3 ± 5284.819774.5 ± 16462.823135.5 ± 19481.4
SecondaryFold Change of Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgG)

Anti-S1-RBD protein Fold Change based on medians = (median value in vaccine only arm / median value in the active arm)

Time frame:
Up to 365 Days from 1st dose of vaccination
Reported as:
Number · Fold Change
Fold Change of Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgG)
Fold ChangeREGN10933+REGN10987 + Vaccine 1200 mg Day 1 IVREGN10933+REGN10987 + Vaccine 300 mg Day 1 IVREGN10933+REGN10987 + Vaccine 150 mg Day 1 IVREGN10933+REGN10987 + Vaccine 48 mg Day 1 IVREGN10933+REGN10987 + Vaccine 12 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 7 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 1 SCREGN10933+REGN10987 + Vaccine 600 mg Day 1 SC
Baseline0.40.71.00.51.01.01.01.0
6 Days after 1st Vaccine—————1.0——
14 Days after 1st Vaccine2.12.33.43.53.01.32.32.6
28 Days after 1st Vaccine2.83.54.22.64.02.22.22.7
42 Days after 1st Vaccine1.11.31.51.01.41.31.31.2
56 Days after 1st Vaccine1.11.31.81.21.31.51.51.6
168 Days after 1st Vaccine1.81.61.50.40.90.31.31.5
252 Days after 1st Vaccine0.91.90.91.51.80.71.11.5
365 Days after 1st Vaccine0.70.60.81.41.61.40.50.4
SecondaryRelative Difference Expressed as a Percent in Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgG)

Anti-S1-RBD protein Relative difference is calculated as: \[(LS Geometric Mean Active Arm - LS Geometric Mean Vaccine Alone Arm) / LS Geometric Mean Vaccine Alone Arm\] x 100%

Time frame:
Up to 365 Days from 1st dose of vaccination
Reported as:
Geometric least squares mean · Percent
Relative Difference Expressed as a Percent in Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgG)
PercentREGN10933+REGN10987 + Vaccine 1200 mg Day 1 IVREGN10933+REGN10987 + Vaccine 300 mg Day 1 IVREGN10933+REGN10987 + Vaccine 150 mg Day 1 IVREGN10933+REGN10987 + Vaccine 48 mg Day 1 IVREGN10933+REGN10987 + Vaccine 12 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 7 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 1 SCREGN10933+REGN10987 + Vaccine 600 mg Day 1 SC
Baseline58.3 (13.8 to 120.2)7.3 (-22.9 to 49.4)-13.0 (-37.5 to 21.1)27.5 (-7.7 to 76.1)25.8 (-10.4 to 76.5)18.2 (-16.2 to 66.7)-14.3 (-37.2 to 17.0)-9.0 (-33.4 to 24.4)
6 Days after 1st Vaccine—————43.3 (-72.8 to 654.8)——
14 Days after 1st Vaccine-35.5 (-67.0 to 26.1)-53.3 (-76.3 to -7.7)-59.9 (-79.7 to -20.9)-38.5 (-68.1 to 18.4)-56.2 (-78.0 to -12.9)-16.4 (-58.0 to 66.5)-44.1 (-70.4 to 5.6)-39.1 (-67.7 to 14.8)
28 Days after 1st Vaccine-50.8 (-74.3 to -6.0)-66.0 (-82.2 to -34.8)-71.3 (-85.0 to -45.0)-43.2 (-69.8 to 7.1)-60.6 (-79.7 to -23.4)-40.7 (-69.5 to 15.2)-46.4 (-70.9 to -1.5)-52.0 (-74.0 to -11.5)
42 Days after 1st Vaccine-11.8 (-45.9 to 43.7)-41.2 (-63.7 to -4.6)-40.7 (-63.4 to -3.8)-0.0 (-37.6 to 60.3)-44.0 (-66.6 to -6.1)-46.4 (-68.3 to -9.4)-30.3 (-55.8 to 9.8)-27.5 (-54.3 to 15.1)
56 Days after 1st Vaccine14.8 (-29.8 to 87.5)-29.3 (-56.2 to 14.2)-34.5 (-59.4 to 5.8)-0.3 (-37.6 to 59.2)-10.8 (-46.2 to 47.8)-19.1 (-51.2 to 34.1)-28.3 (-54.4 to 12.5)-14.2 (-45.7 to 35.6)
168 Days after 1st Vaccine-26.0 (-62.0 to 44.1)-50.5 (-74.4 to -4.3)-20.4 (-58.4 to 52.6)60.7 (-16.8 to 210.5)-3.1 (-51.2 to 92.5)135.3 (17.4 to 371.6)-45.2 (-70.4 to 1.8)-45.2 (-70.6 to 2.1)
252 Days after 1st Vaccine-3.9 (-61.0 to 136.6)-48.3 (-79.1 to 27.6)10.5 (-54.2 to 166.3)-6.6 (-63.1 to 136.6)-1.4 (-63.3 to 164.8)48.4 (-42.8 to 285.2)19.1 (-50.2 to 184.7)1.8 (-56.5 to 138.4)
365 Days after 1st Vaccine102.8 (4.5 to 293.4)63.5 (-15.1 to 214.7)45.5 (-22.5 to 173.1)2.7 (-46.6 to 97.5)-14.9 (-58.1 to 72.6)-27.8 (-63.5 to 42.8)82.8 (-2.0 to 241.1)145.7 (33.6 to 351.9)
SecondaryAbsolute Values in Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgM)

Anti-S1-RBD

Time frame:
Up to 365 Days from 1st dose of vaccination
Reported as:
Mean · Binding Antibody Unit (BAU)/mL
Absolute Values in Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgM)
Binding Antibody Unit (BAU)/mLVaccine OnlyREGN10933+REGN10987 + Vaccine 1200 mg Day 1 IVREGN10933+REGN10987 + Vaccine 300 mg Day 1 IVREGN10933+REGN10987 + Vaccine 150 mg Day 1 IVREGN10933+REGN10987 + Vaccine 48 mg Day 1 IVREGN10933+REGN10987 + Vaccine 12 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 7 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 1 SCREGN10933+REGN10987 + Vaccine 600 mg Day 1 SC
Baseline7.0 ± 7.37.1 ± 5.27.5 ± 7.76.4 ± 4.16.5 ± 6.86.9 ± 4.27.0 ± 4.96.1 ± 3.25.7 ± 2.6
6 Days after 1st Vaccine8.9 ± 6.8—————13.1 ± 20.9——
14 Days after 1st Vaccine53.8 ± 70.829.2 ± 38.725.5 ± 26.235.1 ± 64.5852.6 ± 4399.314.3 ± 13.942.3 ± 47.9774.5 ± 4180.734.4 ± 81.2
28 Days after 1st Vaccine34.5 ± 32.417.3 ± 22.314.8 ± 16.017.5 ± 25.1848.9 ± 4400.014.2 ± 16.127.3 ± 28.1750.8 ± 4114.917.9 ± 39.7
42 Days after 1st Vaccine55.5 ± 57.238.5 ± 55.920.3 ± 16.821.7 ± 18.3869.2 ± 4396.137.9 ± 33.740.5 ± 38.4762.2 ± 4113.029.0 ± 35.5
56 Days after 1st Vaccine34.1 ± 34.920.6 ± 29.411.8 ± 9.712.2 ± 9.337.0 ± 79.219.8 ± 16.727.1 ± 23.330.9 ± 63.017.6 ± 19.9
168 Days after 1st Vaccine11.7 ± 9.58.9 ± 6.18.7 ± 10.610.8 ± 14.415.8 ± 22.19.4 ± 10.912.1 ± 9.29.1 ± 11.46.5 ± 4.4
252 Days after 1st Vaccine13.6 ± 13.310.2 ± 6.911.1 ± 12.710.5 ± 9.117.9 ± 36.110.2 ± 12.612.8 ± 18.5875.0 ± 4481.716.9 ± 22.8
365 Days after 1st Vaccine9.2 ± 6.58.6 ± 5.68.1 ± 6.49.6 ± 9.713.7 ± 18.37.2 ± 5.714.6 ± 22.810.6 ± 15.711.8 ± 13.5
SecondaryRelative Difference Expressed as a Percent in Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgM)

Anti-S1-RBD protein Relative difference is calculated as: \[(LS Geometric Mean Active Arm - LS Geometric Mean Vaccine Alone Arm) / LS Geometric Mean Vaccine Alone Arm\] x 100%

Time frame:
Up to 365 Days from 1st dose of vaccination
Reported as:
Geometric least squares mean · Percent
Relative Difference Expressed as a Percent in Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgM)
PercentREGN10933+REGN10987 + Vaccine 1200 mg Day 1 IVREGN10933+REGN10987 + Vaccine 300 mg Day 1 IVREGN10933+REGN10987 + Vaccine 150 mg Day 1 IVREGN10933+REGN10987 + Vaccine 48 mg Day 1 IVREGN10933+REGN10987 + Vaccine 12 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 7 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 1 SCREGN10933+REGN10987 + Vaccine 600 mg Day 1 SC
Baseline5.9 (-15.9 to 33.5)3.5 (-17.9 to 30.5)-1.5 (-21.8 to 24.2)-4.7 (-24.1 to 19.5)6.0 (-16.4 to 34.5)3.6 (-18.6 to 31.8)-1.7 (-20.9 to 22.3)-4.9 (-23.6 to 18.4)
14 Days after 1st Vaccine-43.7 (-69.0 to 2.3)-50.9 (-73.2 to -10.0)-54.7 (-75.3 to -16.9)-36.7 (-64.7 to 13.7)-62.8 (-79.9 to -31.3)-10.9 (-51.7 to 64.7)-34.9 (-63.1 to 14.8)-41.0 (-66.5 to 3.8)
28 Days after 1st Vaccine-46.6 (-70.0 to -5.1)-53.6 (-73.9 to -17.3)-53.3 (-73.8 to -17.0)-26.5 (-58.2 to 29.0)-52.0 (-73. to -13.4)-15.5 (-53.2 to 52.5)-27.7 (-57.9 to 24.3)-51.3 (-71.7 to -16.0)
42 Days after 1st Vaccine-22.7 (-56.1 to 36.4)-55.9 (-74.8 to -22.7)-51.5 (-72.3 to -15.1)8.0 (-37.6 to 86.8)-18.2 (-55.1 to 49.2)-20.2 (-56.6 to 46.9)-36.3 (-62.4 to 8.0)-43.0 (-66.7 to -2.5)
56 Days after 1st Vaccine-33.6 (-58.8 to 7.2)-58.2 (-73.8 to -33.2)-56.6 (-72.8 to -30.8)-16.8 (-47.3 to 31.3)-32.9 (-59.0 to 9.8)-14.0 (-47.5 to 40.6)-37.7 (-59.8 to -3.2)-42.3 (-63.1 to -9.8)
168 Days after 1st Vaccine-18.5 (-42.5 to 15.5)-30.5 (-50.8 to -1.8)-17.8 (-41.5 to 15.6)6.8 (-24.3 to 50.8)-23.8 (-46.8 to 9.1)3.2 (-28.3 to 48.5)-27.3 (-47.4 to 0.5)-35.4 (-53.4 to -10.5)
252 Days after 1st Vaccine-15.2 (-48.4 to 39.1)-20.0 (-51.3 to 31.6)-19.3 (-50.3 to 30.9)-17.2 (-50.3 to 38.1)-22.3 (-54.9 to 33.8)-13.0 (-48.5 to 46.9)20.6 (-25.3 to 94.8)6.4 (-33.4 to 69.9)
365 Days after 1st Vaccine-4.0 (-34.7 to 41.1)-12.4 (-40.2 to 28.1)-6.6 (-35.2 to 34.7)8.3 (-26.0 to 58.4)-19.1 (-46.4 to 22.1)13.5 (-23.7 to 68.8)-8.7 (-36.5 to 31.2)8.1 (-24.1 to 54.1)
SecondaryFold Change of Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgM)

Anti-S1-RBD protein Fold Change based on medians = (median value in vaccine only arm / median value in the active arm)

Time frame:
Up to 365 Days from 1st dose of vaccination
Reported as:
Number · Fold Change
Fold Change of Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S1-RBD IgM)
Fold ChangeREGN10933+REGN10987 + Vaccine 1200 mg Day 1 IVREGN10933+REGN10987 + Vaccine 300 mg Day 1 IVREGN10933+REGN10987 + Vaccine 150 mg Day 1 IVREGN10933+REGN10987 + Vaccine 48 mg Day 1 IVREGN10933+REGN10987 + Vaccine 12 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 7 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 1 SCREGN10933+REGN10987 + Vaccine 600 mg Day 1 SC
Baseline1.01.01.01.01.01.01.01.0
14 Days after 1st Vaccine1.91.82.62.43.31.02.12.3
28 Days after 1st Vaccine2.33.15.02.15.01.42.35.0
42 Days after 1st Vaccine2.02.42.81.61.91.53.12.3
56 Days after 1st Vaccine1.52.82.81.11.40.91.71.6
168 Days after 1st Vaccine2.12.12.12.12.10.92.12.1
252 Days after 1st Vaccine2.12.12.12.12.12.12.11.0
365 Days after 1st Vaccine1.01.01.01.01.01.01.01.0
SecondaryAbsolute Values in Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgM)

Anti-S protein (Spike protein)

Time frame:
Up to 365 Days from 1st dose of vaccination
Reported as:
Mean · Binding Antibody Unit (BAU)/mL
Absolute Values in Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgM)
Binding Antibody Unit (BAU)/mLVaccine OnlyREGN10933+REGN10987 + Vaccine 1200 mg Day 1 IVREGN10933+REGN10987 + Vaccine 300 mg Day 1 IVREGN10933+REGN10987 + Vaccine 150 mg Day 1 IVREGN10933+REGN10987 + Vaccine 48 mg Day 1 IVREGN10933+REGN10987 + Vaccine 12 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 7 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 1 SCREGN10933+REGN10987 + Vaccine 600 mg Day 1 SC
Baseline5.1 ± 5.65.7 ± 6.67.1 ± 9.65.7 ± 6.33.9 ± 2.94.8 ± 3.54.3 ± 2.93.7 ± 2.04.3 ± 3.7
6 Days after 1st Vaccine5.0 ± 2.6—————10.0 ± 21.3——
14 Days after 1st Vaccine82.1 ± 84.150.1 ± 61.032.2 ± 33.453.8 ± 99.1579.5 ± 2919.421.4 ± 21.857.9 ± 56.6535.1 ± 2773.153.8 ± 133.3
28 Days after 1st Vaccine52.6 ± 48.324.3 ± 37.218.7 ± 28.823.0 ± 37.656.0 ± 187.741.4 ± 136.934.3 ± 34.755.1 ± 151.023.4 ± 52.6
42 Days after 1st Vaccine86.3 ± 90.057.2 ± 90.231.1 ± 29.530.4 ± 26.3604.2 ± 2914.766.2 ± 85.561.4 ± 57.365.5 ± 111.542.8 ± 47.5
56 Days after 1st Vaccine50.3 ± 58.428.1 ± 44.017.8 ± 20.914.2 ± 10.647.7 ± 96.632.3 ± 39.842.2 ± 43.140.3 ± 74.525.9 ± 29.1
168 Days after 1st Vaccine10.4 ± 9.67.0 ± 6.48.8 ± 12.49.7 ± 14.016.6 ± 21.911.5 ± 13.412.1 ± 8.57.0 ± 10.65.9 ± 4.8
252 Days after 1st Vaccine13.1 ± 13.99.6 ± 6.910.2 ± 11.09.3 ± 6.819.9 ± 45.711.7 ± 13.414.1 ± 18.538.4 ± 147.415.7 ± 19.1
365 Days after 1st Vaccine8.8 ± 7.68.9 ± 6.49.5 ± 9.98.3 ± 6.913.0 ± 20.48.0 ± 6.613.1 ± 18.69.3 ± 10.012.5 ± 13.1
SecondaryRelative Difference Expressed as a Percent in Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgM)

Anti-S protein (Spike protein) Relative difference is calculated as: \[(LS Geometric Mean Active Arm - LS Geometric Mean Vaccine Alone Arm) / LS Geometric Mean Vaccine Alone Arm\] x 100%

Time frame:
Up to 365 Days from 1st dose of vaccination
Reported as:
Least squares mean · Percent
Relative Difference Expressed as a Percent in Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgM)
PercentREGN10933+REGN10987 + Vaccine 1200 mg Day 1 IVREGN10933+REGN10987 + Vaccine 300 mg Day 1 IVREGN10933+REGN10987 + Vaccine 150 mg Day 1 IVREGN10933+REGN10987 + Vaccine 48 mg Day 1 IVREGN10933+REGN10987 + Vaccine 12 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 7 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 1 SCREGN10933+REGN10987 + Vaccine 600 mg Day 1 SC
Baseline8.9 (-16.7 to 42.4)14.7 (-12.4 to 50.1)6.3 (-18.7 to 39.1)-12.1 (-32.4 to 14.3)3.9 (-21.1 to 36.9)-7.3 (-29.9 to 22.6)-13.3 (-32.7 to 11.6)-5.8 (-26.9 to 21.5)
14 Days after 1st Vaccine-42.1 (-69.6 to 10.2)-58.9 (-78.6 to -21.0)-60.1 (-79.2 to -23.3)-54.7 (-75.9 to -15.0)-66.8 (-82.8 to -35.6)-21.8 (-59.6 to 51.5)-40.2 (-67.5 to 10.3)-44.7 (-69.9 to 1.8)
28 Days after 1st Vaccine-56.7 (-76.4 to -20.4)-69.2 (-83.3 to -43.4)-64.6 (-80.7 to -35.0)-50.2 (-72.5 to -9.8)-61.6 (-79.4 to -28.4)-31.7 (-63.4 to 27.4)-52.7 (-73.3 to -16.3)-58.7 (-76.8 to -26.7)
42 Days after 1st Vaccine-32.5 (-60.5 to 15.2)-63.0 (-78.2 to -37.1)-56.9 (-74.6 to -26.8)-7.5 (-44.8 to 55.2)-19.2 (-54.1 to 42.4)-21.1 (-55.6 to 40.1)-46.7 (-67.6 to -12.3)-43.7 (-66.1 to -6.7)
56 Days after 1st Vaccine-37.3 (-63.3 to 6.9)-61.7 (-77.3 to -35.5)-62.8 (-77.9 to -37.3)-20.3 (-52.1 to 32.7)-34.4 (-62.1 to 13.7)-14.4 (-50.6 to 48.2)-45.1 (-66.4 to -10.3)-39.3 (-63.1 to -0.1)
168 Days after 1st Vaccine-29.0 (-53.6 to 8.8)-33.0 (-56.1 to 2.1)-19.5 (-46.9 to 22.0)9.4 (-28.2 to 66.7)-14.8 (-45.0 to 32.2)17.4 (-24.8 to 83.2)-37.2 (-57.7 to -6.7)-35.9 (-57.0 to -4.6)
252 Days after 1st Vaccine-19.7 (-51.3 to 32.5)-31.0 (-58.2 to 14.0)-21.1 (-51.6 to 28.7)-22.1 (-53.5 to 30.5)-17.5 (-52.4 to 42.9)-3.1 (-43.0 to 64.6)-4.5 (-41.2 to 55.0)-2.6 (-39.3 to 56.3)
365 Days after 1st Vaccine4.0 (-33.6 to 62.7)-1.3 (-36.6 to 53.7)-5.7 (-38.4 to 44.3)1.2 (-35.0 to 57.5)-9.5 (-43.9 to 46.0)5.6 (-33.4 to 67.5)-3.0 (-36.4 to 47.8)27.1 (-15.8 to 91.9)
SecondaryFold Change of Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgM)

Anti-S protein (Spike protein) Fold Change based on medians = (median value in vaccine only arm / median value in the active arm)

Time frame:
Up to 365 Days from 1st dose of vaccination
Reported as:
Number · Fold Change
Fold Change of Concentrations of Vaccine-induced Antibodies to SARS-CoV-2 Antigens Over Time (S-IgM)
Fold ChangeREGN10933+REGN10987 + Vaccine 1200 mg Day 1 IVREGN10933+REGN10987 + Vaccine 300 mg Day 1 IVREGN10933+REGN10987 + Vaccine 150 mg Day 1 IVREGN10933+REGN10987 + Vaccine 48 mg Day 1 IVREGN10933+REGN10987 + Vaccine 12 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 7 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 1 SCREGN10933+REGN10987 + Vaccine 600 mg Day 1 SC
Baseline1.01.01.01.01.01.01.01.0
6 Days after 1st Vaccine—————1.0——
14 Days after 1st Vaccine2.12.42.83.22.91.13.02.0
28 Days after 1st Vaccine3.65.24.53.34.91.93.73.7
42 Days after 1st Vaccine2.22.42.61.41.91.32.92.0
56 Days after 1st Vaccine1.72.22.01.11.41.21.81.3
168 Days after 1st Vaccine2.72.71.81.32.70.92.72.7
252 Days after 1st Vaccine1.03.21.43.21.11.01.11.1
365 Days after 1st Vaccine0.91.00.92.22.22.21.10.9
Secondary50% Inhibitory Dilution (ID50) Titers of Vaccine-induced Neutralizing Antibodies to SARS-CoV-2 S Protein Assessed Over Time After the First Dose of Moderna mRNA-1273 Vaccine
Time frame:
Up to 365 Days from 1st dose of vaccination
Reported as:
Mean · Titer
50% Inhibitory Dilution (ID50) Titers of Vaccine-induced Neutralizing Antibodies to SARS-CoV-2 S Protein Assessed Over Time After the First Dose of Moderna mRNA-1273 Vaccine
TiterVaccine OnlyREGN10933+REGN10987 + Vaccine 1200 mg Day 1 IVREGN10933+REGN10987 + Vaccine 300 mg Day 1 IVREGN10933+REGN10987 + Vaccine 150 mg Day 1 IVREGN10933+REGN10987 + Vaccine 48 mg Day 1 IVREGN10933+REGN10987 + Vaccine 12 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 7 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 1 SCREGN10933+REGN10987 + Vaccine 600 mg Day 1 SC
Baseline40.0 ± 0.040.0 ± 0.040.0 ± 0.040.0 ± 0.040.0 ± 0.040.0 ± 0.040.0 ± 0.040.0 ± 0.040.0 ± 0.0
6 Days40.0 ± 0.0—————827.8 ± 3859.4——
14 Days928.4 ± 4600.0518.7 ± 1446.081.0 ± 59.984.2 ± 78.12686.8 ± 9365.3780.4 ± 2955.91847.5 ± 6787.193.3 ± 78.81325.2 ± 6386.1
28 Days640.5 ± 2173.9499.8 ± 1420.1136.2 ± 169.8177.7 ± 581.63887.0 ± 16628.4631.3 ± 1955.2785.6 ± 2134.7113.7 ± 102.01108.3 ± 5103.2
42 Days4391.0 ± 4567.22623.7 ± 2216.81322.6 ± 1198.81284.8 ± 1434.16926.8 ± 14487.03744.3 ± 4066.74351.9 ± 4553.91418.2 ± 1414.82167.2 ± 5160.7
56 Days2594.9 ± 1981.51818.6 ± 2365.8780.8 ± 771.1716.1 ± 664.94922.8 ± 11157.32422.2 ± 2882.72576.8 ± 2736.1980.8 ± 1015.11549.5 ± 4334.1
168 Days2889.5 ± 3890.91756.4 ± 2759.0649.4 ± 791.11670.2 ± 2774.33316.2 ± 4137.51007.5 ± 871.82968.4 ± 3399.81261.4 ± 2139.7974.6 ± 1124.6
252 Days10110.8 ± 11107.83815.0 ± 4058.12712.6 ± 2898.74891.0 ± 5258.54844.8 ± 6960.86491.6 ± 12406.57311.4 ± 8802.47034.7 ± 9548.75041.1 ± 6443.0
365 Days7250.9 ± 6902.07184.3 ± 6172.63934.6 ± 3800.04408.0 ± 3941.07070.1 ± 9060.813175.9 ± 26414.24949.7 ± 4445.66287.3 ± 6023.37174.4 ± 7753.8
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) Throughout the Study
Time frame:
Up to 401 Days
Reported as:
Number · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Throughout the Study
ParticipantsVaccine OnlyREGN10933+REGN10987 + Vaccine 1200 mg Day 1 IVREGN10933+REGN10987 + Vaccine 300 mg Day 1 IVREGN10933+REGN10987 + Vaccine 150 mg Day 1 IVREGN10933+REGN10987 + Vaccine 48 mg Day 1 IVREGN10933+REGN10987 + Vaccine 12 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 7 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 1 SCREGN10933+REGN10987 + Vaccine 600 mg Day 1 SC
Number of Participants With Treatment-emergent Adverse Events (TEAEs) Throughout the Study221316171516131623
SecondaryNumber of Participants With Treatment-emergent Serious Adverse Events (SAEs) Throughout the Study
Time frame:
Up to 401 Days
Reported as:
Number · Participants
Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) Throughout the Study
ParticipantsVaccine OnlyREGN10933+REGN10987 + Vaccine 1200 mg Day 1 IVREGN10933+REGN10987 + Vaccine 300 mg Day 1 IVREGN10933+REGN10987 + Vaccine 150 mg Day 1 IVREGN10933+REGN10987 + Vaccine 48 mg Day 1 IVREGN10933+REGN10987 + Vaccine 12 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 7 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 1 SCREGN10933+REGN10987 + Vaccine 600 mg Day 1 SC
Number of Participants With Treatment-emergent Serious Adverse Events (SAEs) Throughout the Study200000210
SecondaryNumber of Participants With Infusion-related Reactions (Grade ≥2) to REGN10933+REGN10987
Time frame:
Through Day 4 post-infusion
Reported as:
Number · Participants
Number of Participants With Infusion-related Reactions (Grade ≥2) to REGN10933+REGN10987
ParticipantsVaccine OnlyREGN10933+REGN10987 + Vaccine 1200 mg Day 1 IVREGN10933+REGN10987 + Vaccine 300 mg Day 1 IVREGN10933+REGN10987 + Vaccine 150 mg Day 1 IVREGN10933+REGN10987 + Vaccine 48 mg Day 1 IVREGN10933+REGN10987 + Vaccine 12 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 7 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 1 SCREGN10933+REGN10987 + Vaccine 600 mg Day 1 SC
Number of Participants With Infusion-related Reactions (Grade ≥2) to REGN10933+REGN10987000000000
SecondaryNumber of Participants With Injection Site Reactions (Grade ≥3) to REGN10933+REGN10987
Time frame:
Through Day 4 post-infusion
Reported as:
Number · Participants
Number of Participants With Injection Site Reactions (Grade ≥3) to REGN10933+REGN10987
ParticipantsVaccine OnlyREGN10933+REGN10987 + Vaccine 1200 mg Day 1 IVREGN10933+REGN10987 + Vaccine 300 mg Day 1 IVREGN10933+REGN10987 + Vaccine 150 mg Day 1 IVREGN10933+REGN10987 + Vaccine 48 mg Day 1 IVREGN10933+REGN10987 + Vaccine 12 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 7 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 1 SCREGN10933+REGN10987 + Vaccine 600 mg Day 1 SC
Number of Participants With Injection Site Reactions (Grade ≥3) to REGN10933+REGN10987000000000
SecondaryNumber of Participants With Injection Site Reactions (Grade ≥3) to Moderna mRNA-1273 Vaccine
Time frame:
Through Day 4 post-infusion
Reported as:
Number · Participants
Number of Participants With Injection Site Reactions (Grade ≥3) to Moderna mRNA-1273 Vaccine
ParticipantsVaccine OnlyREGN10933+REGN10987 + Vaccine 1200 mg Day 1 IVREGN10933+REGN10987 + Vaccine 300 mg Day 1 IVREGN10933+REGN10987 + Vaccine 150 mg Day 1 IVREGN10933+REGN10987 + Vaccine 48 mg Day 1 IVREGN10933+REGN10987 + Vaccine 12 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 7 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 1 SCREGN10933+REGN10987 + Vaccine 600 mg Day 1 SC
Number of Participants With Injection Site Reactions (Grade ≥3) to Moderna mRNA-1273 Vaccine000000000
SecondaryNumber of Participants With Hypersensitivity Reactions (Grade ≥2) to REGN10933+REGN10987 or Each Dose of Moderna mRNA-1273 Vaccine

Grade 2 - characterized by an adverse local or general response from exposure and oral intervention indicated Grade 3 - hospitalization indicated and intravenous response required Grade 4 - Life Threatening consequence and urgent intervention indicated Grade 5 - Death

Time frame:
Through Day 29 post-infusion or post-injection
Reported as:
Number · Participants
Number of Participants With Hypersensitivity Reactions (Grade ≥2) to REGN10933+REGN10987 or Each Dose of Moderna mRNA-1273 Vaccine
ParticipantsVaccine OnlyREGN10933+REGN10987 + Vaccine 1200 mg Day 1 IVREGN10933+REGN10987 + Vaccine 300 mg Day 1 IVREGN10933+REGN10987 + Vaccine 150 mg Day 1 IVREGN10933+REGN10987 + Vaccine 48 mg Day 1 IVREGN10933+REGN10987 + Vaccine 12 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 7 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 1 SCREGN10933+REGN10987 + Vaccine 600 mg Day 1 SC
Number of Participants With Hypersensitivity Reactions (Grade ≥2) to REGN10933+REGN10987 or Each Dose of Moderna mRNA-1273 Vaccine000000001
SecondaryConcentrations of REGN10933 in Serum Over Time
Time frame:
Up to 182 Days
Reported as:
Mean · mg/L
Concentrations of REGN10933 in Serum Over Time
mg/LREGN10933+REGN10987 + Vaccine 1200 mg Day 1 IVREGN10933+REGN10987 + Vaccine 300 mg Day 1 IVREGN10933+REGN10987 + Vaccine 150 mg Day 1 IVREGN10933+REGN10987 + Vaccine 48 mg Day 1 IVREGN10933+REGN10987 + Vaccine 12 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 7 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 1 SCREGN10933+REGN10987 + Vaccine 600 mg Day 1 SC
0 Days (Pre-dose)0.0219 ± 0.1140 ± 00 ± 00 ± 00 ± 05.12 ± 26.10 ± 00 ± 0
0 Days (End of Infusion)145 ± 40.840.5 ± 16.226.8 ± 16.97.84 ± 4.281.84 ± 0.593140 ± 54.40.527 ± 0.9660.0765 ± 0.160
8 Days—————63.7 ± 11.7——
14 Days46.8 ± 11.312.7 ± 3.798.30 ± 3.942.62 ± 1.440.536 ± 0.229—39.4 ± 11.520.4 ± 7.48
22 Days—————39.1 ± 10.9——
28 Days29.5 ± 9.898.24 ± 3.025.12 ± 2.281.76 ± 1.130.354 ± 0.150—26.0 ± 8.0414.7 ± 6.25
36 Days—————27.7 ± 7.80——
42 Days18.7 ± 7.985.38 ± 2.403.35 ± 1.711.19 ± 0.8610.237 ± 0.114—17.5 ± 6.309.77 ± 5.01
50 Days—————19.3 ± 5.45——
56 Days13.4 ± 5.873.51 ± 1.782.10 ± 1.140.754 ± 0.5690.131 ± 0.142—11.6 ± 5.046.70 ± 3.77
70 Days9.98 ± 6.062.34 ± 1.331.42 ± 0.8040.522 ± 0.4560.0105 ± 0.0408———
162 Days—————1.38 ± 1.00——
168 Days——————0.891 ± 0.7120.615 ± 0.797
182 Days0.898 ± 1.060.180 ± 0.2120.137 ± 0.3560.00693 ± 0.03600 ± 0———
SecondaryConcentrations of REGN10987 in Serum Over Time
Time frame:
Up to 182 Days
Reported as:
Mean · mg/L
Concentrations of REGN10987 in Serum Over Time
mg/LREGN10933+REGN10987 + Vaccine 1200 mg Day 1 IVREGN10933+REGN10987 + Vaccine 300 mg Day 1 IVREGN10933+REGN10987 + Vaccine 150 mg Day 1 IVREGN10933+REGN10987 + Vaccine 48 mg Day 1 IVREGN10933+REGN10987 + Vaccine 12 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 7 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 1 SCREGN10933+REGN10987 + Vaccine 600 mg Day 1 SC
0 Days (Pre-dose)0.0223 ± 0.1160 ± 00 ± 00 ± 00 ± 06.00 ± 30.60 ± 00.00577 ± 0.0341
0 Days (End of Infusion)144 ± 42.539.6 ± 15.528.9 ± 26.78.60 ± 5.101.91 ± 0.687150 ± 58.00.580 ± 0.7770.232 ± 0.614
8 Days—————61.6 ± 12.0——
14 Days40.0 ± 11.211.2 ± 3.417.20 ± 3.092.33 ± 1.370.438 ± 0.226—33.8 ± 9.5118.0 ± 6.15
22 Days—————35.0 ± 10.5——
28 Days23.8 ± 9.926.87 ± 2.844.19 ± 1.951.46 ± 0.9680.263 ± 0.189—21.0 ± 6.9512.1 ± 5.92
36 Days—————22.2 ± 6.56——
42 Days13.7 ± 6.864.00 ± 2.022.54 ± 1.350.868 ± 0.6410.138 ± 0.147—13.3 ± 6.117.71 ± 4.42
50 Days—————14.5 ± 4.09——
56 Days9.23 ± 4.972.51 ± 1.481.55 ± 0.9030.507 ± 0.4530.0776 ± 0.138—8.02 ± 3.994.86 ± 3.07
70 Days6.51 ± 4.531.57 ± 1.040.993 ± 0.6300.306 ± 0.3440.0115 ± 0.0444———
162 Days—————0.566 ± 0.560——
168 Days——————0.347 ± 0.3780.251 ± 0.465
182 Days0.400 ± 0.6170.0401 ± 0.1240.0408 ± 0.1790 ± 00 ± 0———
SecondaryImmunogenicity, as Measured by Anti-drug Antibodies (ADA) to REGN10987
Time frame:
Up to Day 183
Reported as:
Number · Percent of Participants
Immunogenicity, as Measured by Anti-drug Antibodies (ADA) to REGN10987
Percent of ParticipantsREGN10933+REGN10987 + Vaccine 1200 mg Day 1 IVREGN10933+REGN10987 + Vaccine 300 mg Day 1 IVREGN10933+REGN10987 + Vaccine 150 mg Day 1 IVREGN10933+REGN10987 + Vaccine 48 mg Day 1 IVREGN10933+REGN10987 + Vaccine 12 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 7 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 1 SCREGN10933+REGN10987 + Vaccine 600 mg Day 1 SC
Negative48.155.644.446.756.756.555.957.1
Pre-Existing Immunoreactivity7.403.73.33.38.705.7
Treatment-Boosted Response0003.3002.90
SecondaryImmunogenicity, as Measured by Anti-drug Antibodies (ADA) to REGN10933
Time frame:
Up to Day 183
Reported as:
Number · Percent of Participants
Immunogenicity, as Measured by Anti-drug Antibodies (ADA) to REGN10933
Percent of ParticipantsREGN10933+REGN10987 + Vaccine 1200 mg Day 1 IVREGN10933+REGN10987 + Vaccine 300 mg Day 1 IVREGN10933+REGN10987 + Vaccine 150 mg Day 1 IVREGN10933+REGN10987 + Vaccine 48 mg Day 1 IVREGN10933+REGN10987 + Vaccine 12 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 7 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 1 SCREGN10933+REGN10987 + Vaccine 600 mg Day 1 SC
Negative66.759.344.430.036.791.370.662.9
Pre-Existing Immunoreactivity03.73.76.70000
Treatment-Boosted Response00000000
SecondaryImmunogenicity, as Measured by Neutralizing Antibodies (NAb) to REGN10987
Time frame:
Up to Day 183
Reported as:
Count of participants · Participants
Immunogenicity, as Measured by Neutralizing Antibodies (NAb) to REGN10987
ParticipantsREGN10933+REGN10987 + Vaccine 1200 mg Day 1 IVREGN10933+REGN10987 + Vaccine 300 mg Day 1 IVREGN10933+REGN10987 + Vaccine 150 mg Day 1 IVREGN10933+REGN10987 + Vaccine 48 mg Day 1 IVREGN10933+REGN10987 + Vaccine 12 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 7 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 1 SCREGN10933+REGN10987 + Vaccine 600 mg Day 1 SC
NAb Negative1612161720152422
NAb Positive11611131081013
SecondaryImmunogenicity, as Measured by Neutralizing Antibodies (NAb) to REGN10933
Time frame:
Up to Day 183
Reported as:
Count of participants · Participants
Immunogenicity, as Measured by Neutralizing Antibodies (NAb) to REGN10933
ParticipantsREGN10933+REGN10987 + Vaccine 1200 mg Day 1 IVREGN10933+REGN10987 + Vaccine 300 mg Day 1 IVREGN10933+REGN10987 + Vaccine 150 mg Day 1 IVREGN10933+REGN10987 + Vaccine 48 mg Day 1 IVREGN10933+REGN10987 + Vaccine 12 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 7 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 1 SCREGN10933+REGN10987 + Vaccine 600 mg Day 1 SC
NAb Negative2725262223213232
Nab Positive02187223

Adverse events

Collected over Up to 401 Days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vaccine Only Total All0/48 (0%)2/48 (4.2%)11/48 (22.9%)
REGN10933+REGN10987 + Vaccine 1200 mg Day 1 IV0/28 (0%)0/28 (0%)13/28 (46.4%)
REGN10933+REGN10987 + Vaccine 300 mg Day 1 IV0/29 (0%)0/29 (0%)9/29 (31%)
REGN10933+REGN10987 + Vaccine 150 mg Day 1 IV0/28 (0%)0/28 (0%)14/28 (50%)
REGN10933+REGN10987 + Vaccine 1200 mg Day 1 SC0/35 (0%)1/35 (2.9%)15/35 (42.9%)
REGN10933+REGN10987 + Vaccine 600 mg Day 1 SC0/35 (0%)0/35 (0%)23/35 (65.7%)
REGN10933+REGN10987 + Vaccine 48 mg Day 1 IV0/33 (0%)0/33 (0%)12/33 (36.4%)
REGN10933+REGN10987 + Vaccine 12 mg Day 1 IV0/31 (0%)0/31 (0%)14/31 (45.2%)
REGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV1/26 (3.8%)2/26 (7.7%)9/26 (34.6%)
Most frequent serious events
Most frequent serious events
EventVaccine Only Total AllREGN10933+REGN10987 + Vaccine 1200 mg Day 1 IVREGN10933+REGN10987 + Vaccine 300 mg Day 1 IVREGN10933+REGN10987 + Vaccine 150 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 1 SCREGN10933+REGN10987 + Vaccine 600 mg Day 1 SCREGN10933+REGN10987 + Vaccine 48 mg Day 1 IVREGN10933+REGN10987 + Vaccine 12 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV
AnaemiaBlood and lymphatic system disorders0/480/280/290/280/350/350/330/311/26
Road traffic accidentInjury, poisoning and procedural complications0/480/280/290/280/350/350/330/311/26
GastritisGastrointestinal disorders0/480/280/290/281/350/350/330/310/26
CholelithiasisHepatobiliary disorders1/480/280/290/280/350/350/330/310/26
Diabetic foot infectionInfections and infestations1/480/280/290/280/350/350/330/310/26
Most frequent other events
Showing 10 of 11
Most frequent other events
EventVaccine Only Total AllREGN10933+REGN10987 + Vaccine 1200 mg Day 1 IVREGN10933+REGN10987 + Vaccine 300 mg Day 1 IVREGN10933+REGN10987 + Vaccine 150 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 1 SCREGN10933+REGN10987 + Vaccine 600 mg Day 1 SCREGN10933+REGN10987 + Vaccine 48 mg Day 1 IVREGN10933+REGN10987 + Vaccine 12 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 7 IV
Injection site reactionGeneral disorders2/482/281/291/287/3512/351/331/315/26
Asymptomatic COVID-19Infections and infestations3/482/284/299/286/357/354/334/311/26
COVID-19Infections and infestations5/487/283/293/287/356/350/336/313/26
HeadacheNervous system disorders3/481/281/291/282/354/353/333/311/26
PyrexiaGeneral disorders0/481/280/290/280/353/352/331/312/26
Upper respiratory tract infectionInfections and infestations0/482/281/290/281/350/350/330/310/26
ArthralgiaMusculoskeletal and connective tissue disorders0/482/281/290/280/350/351/332/310/26
CellulitisInfections and infestations0/480/280/290/281/350/350/332/310/26
ChillsGeneral disorders0/481/280/290/280/351/352/330/311/26
HypertensionVascular disorders1/481/281/290/280/351/352/330/311/26

Baseline characteristics

The safety analysis set (SAF) includes all randomized subjects who have been vaccinated with at least one dose or received any study drug

Age, Customized
Age, Customized(years)Vaccine OnlyREGN10933+REGN10987 + Vaccine 1200 mg Day 1 IVREGN10933+REGN10987 + Vaccine 300 mg Day 1 IVREGN10933+REGN10987 + Vaccine 150 mg Day 1 IVREGN10933+REGN10987 + Vaccine 48 mg Day 1 IVREGN10933+REGN10987 + Vaccine 12 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 7 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 1 SCREGN10933+REGN10987 + Vaccine 600 mg Day 1 SCTotal
Mean40.2 ± 12.1741.8 ± 13.9839.3 ± 12.7639.7 ± 13.5041.6 ± 12.7341.1 ± 11.2339.8 ± 13.7643.8 ± 12.9946.3 ± 11.5341.6 ± 12.70
Sex: Female, Male
Sex: Female, Male(Participants)Vaccine OnlyREGN10933+REGN10987 + Vaccine 1200 mg Day 1 IVREGN10933+REGN10987 + Vaccine 300 mg Day 1 IVREGN10933+REGN10987 + Vaccine 150 mg Day 1 IVREGN10933+REGN10987 + Vaccine 48 mg Day 1 IVREGN10933+REGN10987 + Vaccine 12 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 7 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 1 SCREGN10933+REGN10987 + Vaccine 600 mg Day 1 SCTotal
Female28139131716141419143
Male201520151615122116150
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Vaccine OnlyREGN10933+REGN10987 + Vaccine 1200 mg Day 1 IVREGN10933+REGN10987 + Vaccine 300 mg Day 1 IVREGN10933+REGN10987 + Vaccine 150 mg Day 1 IVREGN10933+REGN10987 + Vaccine 48 mg Day 1 IVREGN10933+REGN10987 + Vaccine 12 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 7 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 1 SCREGN10933+REGN10987 + Vaccine 600 mg Day 1 SCTotal
Hispanic or Latino1691291619171112121
Not Hispanic or Latino31191719171292423171
Unknown or Not Reported1000000001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Vaccine OnlyREGN10933+REGN10987 + Vaccine 1200 mg Day 1 IVREGN10933+REGN10987 + Vaccine 300 mg Day 1 IVREGN10933+REGN10987 + Vaccine 150 mg Day 1 IVREGN10933+REGN10987 + Vaccine 48 mg Day 1 IVREGN10933+REGN10987 + Vaccine 12 mg Day 1 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 7 IVREGN10933+REGN10987 + Vaccine 1200 mg Day 1 SCREGN10933+REGN10987 + Vaccine 600 mg Day 1 SCTotal
American Indian or Alaska Native0001010013
Asian0000110103
Native Hawaiian or Other Pacific Islander0000010001
Black or African American16107997710782
White321822182321192427204
More than one race0000000000
Unknown or Not Reported0000000000
08

Study locations

6 sites
  • Regeneron Research Site
    Little Rock, Arkansas 72211, United States
  • Regeneron Research Site
    Rogers, Arkansas 72758, United States
  • Regeneron Research Site
    Hialeah, Florida 33012, United States
  • Regeneron Research Site
    Miami, Florida 33186, United States
  • Regeneron Research Site
    Orlando, Florida 32789, United States
  • Regeneron Research Site
    Dayton, Ohio 45417, United States
09

References and documents

Publications

  • Isa F, Gonzalez Ortiz AM, Meyer J, Hamilton JD, Olenchock BA, Brackin T, Ganguly S, Forleo-Neto E, Faria L, Heirman I, Marovich M, Hutter J, Polakowski L, Irvin SC, Thakur M, Hooper AT, Baum A, Petro CD, Fakih FA, McElrath MJ, De Rosa SC, Cohen KW, Williams LD, Hellman CA, Odeh AJ, Patel AH, Tomaras GD, Geba GP, Kyratsous CA, Musser B, Yancopoulos GD, Herman GA; Trial Working Group. Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial. Lancet Infect Dis. 2025 Jan;25(1):52-67. doi: 10.1016/S1473-3099(24)00421-3. Epub 2024 Sep 2. PubMed 39236733 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.

Access criteria: Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2021 to primary completion in Nov 2022, 18 months.

Results were first posted in Aug 2024, 1 year 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2021
First posted
Apr 21, 2021
StartActual
Apr 29, 2021
Primary completionActual
Nov 21, 2022
CompletionActual
Nov 21, 2022
Results first posted
Aug 20, 2024
Last update
Oct 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04852978
Responsible party
Sponsor
First posted
Apr 21, 2021
Start date
Apr 29, 2021
Primary completion
Nov 21, 2022
Completion
Nov 21, 2022
Results posted
Aug 20, 2024
Last update
Oct 20, 2025

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion